Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553265 · ClinicalTrials.gov registry record · Phase 2
Carbidopa for the Treatment of Excessive Blood Pressure Variability
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02553265 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 22 participants.
The verdict
NCT02553265, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated blood pressure variability in patients with familial dysautonomia (FD, also called hereditary sensory and autonomic neuropathy type III or Riley-Day syndrome). Funding Source- FDA OOPD.
Interventions
- OTHER Placebo
- DRUG Carbidopa Low-Dose
- DRUG Carbidopa High-Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553265
The ClinicalTrials.gov registry entry for NCT02553265 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02553265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02553265 about?
NCT02553265 is a clinical study titled "Carbidopa for the Treatment of Excessive Blood Pressure Variability". The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated blood pressure variability in patients with familial dysautonomia (FD, also...
What is the current status of trial NCT02553265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-09. Estimated completion is 2019-05-10.
What interventions are being tested in trial NCT02553265?
The interventions under investigation include: Placebo (OTHER), Carbidopa Low-Dose (DRUG), Carbidopa High-Dose (DRUG).
Who is sponsoring clinical trial NCT02553265?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.